Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables
The characteristics of the host are crucial in the final outcome of COVID-19. Herein, the influence of genetic and clinical variants in COVID-19 severity was investigated in a total of 1350 patients. Twenty-one single nucleotide polymorphisms of genes involved in SARS-CoV-2 sensing as Toll-like-Receptor 7, antiviral immunity as the type I interferon signalling pathway (TYK2, STAT1, STAT4, OAS1, SOCS) and the vasoactive intestinal peptide and its receptors (VIP/VIPR1,2) were studied. To analyse the association between polymorphisms and severity, a model adjusted by age, sex and different comorbidities was generated by ordinal logistic regression. The genotypes rs8108236-AA (OR 0.12 [95% CI 0.02-0.53]; p = 0.007) and rs280519-AG (OR 0.74 [95% CI 0.56-0.99]; p = 0.03) in TYK2, and rs688136-CC (OR 0.7 [95% CI 0.5-0.99]; p = 0.046) in VIP, were associated with lower severity; in contrast, rs3853839-GG in TLR7 (OR 1.44 [95% CI 1.07-1.94]; p = 0.016), rs280500-AG (OR 1.33 [95% CI 0.97-1.82]; p = 0.078) in TYK2 and rs1131454-AA in OAS1 (OR 1.29 [95% CI 0.95-1.75]; p = 0.110) were associated with higher severity. Therefore, these variants could influence the risk of severe COVID-19.
Authors
- Gonzalo Villapalos‐García (ORCID: https://orcid.org/0000-0002-4849-3268)
- Francisco Abad‐Santos (ORCID: https://orcid.org/0000-0002-6519-8885)
- Isidoro González‐Álvaro (ORCID: https://orcid.org/0000-0001-9614-5199)
- Diego Rodríguez (ORCID: https://orcid.org/0000-0003-1841-2751)
- Sara Fernández de Córdoba‐Oñate (ORCID: https://orcid.org/0009-0004-5686-3486)
- Pablo Zubiaur (ORCID: https://orcid.org/0000-0002-6150-4320)
- Elena Fernández‐Ruiz (ORCID: https://orcid.org/0000-0001-5380-1686)
- Amalia Lamana (ORCID: https://orcid.org/0000-0001-8779-5034)
- Ana Marcos‐Jiménez (ORCID: https://orcid.org/0000-0002-7606-3580)
- Rosa P. Gomariz (ORCID: https://orcid.org/0000-0003-2839-1923)
- Estíbaliz Alegría‐Carrasco (ORCID: https://orcid.org/0000-0001-7119-4920)
- Cecilia Muñoz‐Calleja (ORCID: https://orcid.org/0000-0003-4085-3115)
- Emilia Roy‐Vallejo
- Núria Montés (ORCID: https://orcid.org/0000-0001-9526-2772)
- Pablo Delgado‐Wicke (ORCID: https://orcid.org/0000-0003-3988-3704)
- José María Galván‐Román (ORCID: https://orcid.org/0000-0001-9260-8141)
- Rosario García‐Vicuña (ORCID: https://orcid.org/0000-0001-9096-3780)
- Paula Díaz-Fernández (ORCID: https://orcid.org/0000-0003-3770-5197)
- Rosa Carracedo-Rodríguez
- Ana Nicolao-Gómez
- Almudena Villa-Martí
- Laura Rabes-Rodríguez
- Marta Sanz-Alba
- Carlos Rodríguez-Franco
- Jesús Álvarez-Rodríguez
- Ignacio De Los Santos (ORCID: https://orcid.org/0000-0001-7073-5211)
Institutions
- Universidad San Pablo CEU (ES)
- Universidad Complutense de Madrid (ES)
- Instituto de Salud Carlos III (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Universitario de La Princesa (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Scientific Reports
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1038/s41598-024-71476-2
- Citations
- 11
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.28
Funders
- Banco Santander
- Comunidad de Madrid
- European Commission
- Universidad Autónoma de Madrid
- Ministerio de Ciencia e Innovación
- Instituto de Salud Carlos III
- European Regional Development Fund